ECP
AEON icon

Empyrean Capital Partners’s AEON Biopharma AEON Stock Holding History

Empyrean Capital Partners’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,778
Closed -$1.42M – 74
2023
Q2 		$1.42M Hold
2,778
– – 0.06% 59
2023
Q1 		$2.03M Sell
2,778
-16,666
-86% -$12.1M 0.07% 75
2022
Q4 		$14.1M Hold
19,444
– – 0.44% 58
2022
Q3 		$13.8M Hold
19,444
– – 0.43% 66
2022
Q2 		$13.7M Hold
19,444
– – 0.44% 78
2022
Q1 		$13.7M Hold
19,444
– – 0.3% 86
2021
Q4 		$13.6M Hold
19,444
– – 0.36% 75
2021
Q3 		$13.6M Buy
+19,444
New +$13.6M 0.3% 87

Other funds holding AEON

ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Empyrean Capital Partners's AEON Position: Q3 2023 in Review

Empyrean Capital Partners sold out of AEON Biopharma (AEON) in Q3 2023, closing a stake of 2,778 shares — an estimated $1.42M sold.

Empyrean Capital Partners first reported a position in AEON in Q3 2021 and held it in 8 quarters. The position peaked at $14.1M in Q4 2022. 15 funds tracked by Wall St. Rank hold AEON as of Q3 2023.

  • Empyrean Capital Partners reported no remaining AEON Biopharma position as of Q3 2023 after selling out during the quarter.
  • Empyrean Capital Partners sold 2,778 AEON Biopharma shares in Q3 2023, an estimated $1.42M.
  • Empyrean Capital Partners first reported a position in AEON Biopharma in Q3 2021 and held it in 8 quarters.
  • Empyrean Capital Partners's AEON Biopharma position peaked at $14.1M in Q4 2022.
  • 15 funds tracked by Wall St. Rank held AEON Biopharma as of Q3 2023.

Based on Empyrean Capital Partners's 13F filing for Q3 2023, filed 14 Nov 2023.